Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
Regular dividend to remain primary capital allocation priority
For full year 2023, the company expects revenue and Adjusted EBITDA margin to be within the ranges provided on November 2, 2023
For full year 2023 the company expects free cash flow before one-time spin-related costs to be above previously provided range
For full year 2024, the company expects revenue to grow in the low-single-digit range on a constant currency basis, and to achieve stable to improving Adjusted EBITDA margin
The company's annual dividend of $1.12 per share remains its primary capital allocation priority, followed by a balance of discretionary debt repayment and opportunistic business development
O
